PositiveID’s Handheld Bio-Threat Testing Device Featured in Computerworld
PositiveID’s Firefly prototype device could be used to detect viruses such as Ebola and other bio-threats
PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that its Firefly Dx system, designed to deliver molecular diagnostic results rapidly at the point-of-need, which could be used to detect Ebola and other biological threats, was recently featured in Computerworld.
About Firefly
PositiveID’s Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan(R) PCR (polymerase chain reaction) chemistry. Firefly is being developed to meet the growing need in healthcare and molecular diagnostics markets for more rapid and accurate point-of-need diagnostics that will enable hospitals, physicians, military personnel, and others to save lives. Firefly can derive results from a sample in less than 20 minutes, at the point of need, compared to two to four hours for a lab device, which would enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems.